Terns Pharmaceuticals, Inc. (TERN) News
Filter TERN News Items
TERN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TERN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest TERN News From Around the Web
Below are the latest news stories about TERNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TERN as an investment opportunity.
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare ConferenceFOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025 at 4:30 p.m. PT. A live webcast of the presentation will be available on the investor rela |
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of January 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equit |
Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Terns Pharmaceuticals, Inc. (NASDAQ:TERN) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have at […] |
Terns Pharmaceuticals CEO & Director Acquires 423% More StockPotential Terns Pharmaceuticals, Inc. ( NASDAQ:TERN ) shareholders may wish to note that the CEO & Director, Amy... |
Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid LeukemiaCompelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels Encouraging safety profile with no dose limiting toxicities, adverse event-related treatment discontinuations, or dose reductions across three dose escalation cohorts High levels of target coverage achieved with once daily dosing at all doses Completion of dose escalation and initiation of dose expansion expected in 1H25 Additional efficacy data expected in 4Q |
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of DirectorsAccomplished biotechnology CEO brings 25 years of strategic, operational, and legal experienceFOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc. |
We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate UpdatesInterim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL tyrosine kinase inhibitor) in chronic myeloid leukemia (CML) expected in early December 2024 Plans to initiate Phase 2 clinical trial for TERN-601 in obesity in early 2Q25 with initial 12-week data expected in 2H25 Cash, cash equivalents and marketable securities of $372.8 million, including $172.7 million equity raise in September, expected to provide runway into 2028 FOSTER CITY, |
Terns Pharmaceuticals to Participate in Upcoming November Investor ConferencesFOSTER CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in November. UBS Global Healthcare ConferenceFormat: Fireside Chat Date and Time: Wednesday |
Insiders Snap Up These 2 ‘Strong Buy’ StocksLet’s talk about insider trading. Not the illegal kind, but the perfectly normal – and fully legal – trading by top-level corporate officers. These are the C-suite residents and the members of the Boards, company officers who know what’s going on behind the scenes and are responsible to shareholders for bringing in profits. They typically hold shares in their own companies and make trades based on the knowledge they have from behind the scenes. To keep the playing field level, federal regulators |